Another wow for sure. Seriously, KITE takes down T-Cell and investors scoop up the shares driving the stock up 18% adding $450 million to the already inflated market cap. Maybe it works and maybe it fails, but one thing is for sure: this is a truly amazing phenomenon. SMZ
Vertex pulled Incivek, Merck pulls Victrelis, and what will J&J do with the other HEP C compound competing against Gilead and Abbvie? Merck has a few rabbits up their sleeve with a potential approval this year and some M&A, but for now, the battle continues. SMZ
Pharma giant cites 2017 use patent in urging docs, pharmacists to stay away January 15, 2015 | By Tracy Staton Usually, when generic copies of a branded drug hit the market, that's the end of the line for scrapping over patent protection. And usually, when drugmakers are trying to protect their patents, they don't go [...]
Novartis Pharmaceuticals has announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies who offer technologies, products or services that "go beyond the pill" to benefit physicians and patients. "By working with Qualcomm Ventures, Novartis sees the opportunity to take a greater leadership role in introducing new mobile or [...]
This is a nasty chart. Considering this is the major Russian Market Index, it is even nastier. The Rubel is sliding and interest rates are 17%. I don't really practice economics anymore, but this smells a bit like 2007. Don't take this as negativity, just signs of cracks in the foundation.
Shares of Isis Pharmaceuticals closed Friday at an all-time high of $62.32. Isis edged up 45 cents for the day, nosing out the previous record of $61.87, reached Thursday. The Carlsbad biotech is up 63 percent from a year ago, and more than six times its price on Dec. 12, 2012, when it closed at [...]
ig pharma Merck (NYSE:MRK) agreed to buy antibiotic specialist Cubist Pharmaceuticals (NASDAQ:CBST) Monday in a deal valued at $9.5 billion. Cubist soared 35% in the stock market today, while Merck dropped a fraction. Merck is acquiring Cubist for $102 a share in cash, yielding an equity value of $8.4 billion, plus $1.1 billion in net [...]
Merck (NYSE:MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. Read More At Investor's Business Daily: http://news.investors.com/technology/111714-726775-merck-vytorin-cholesterol-drug-study-successful.htm#ixzz3JWnjutCg Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook
